Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Diffusion Tensor Imaging × 1 year × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡